Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 101–200 of 869
Blocking interleukin-1β in acute and chronic autoinflammatory diseases
Dinarello, C. A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02313.x · Cited by 164
CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease
Kuemmerle-Deschner, J. B. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0491-7 · Cited by 145
Self-citationKarimbux, N. Y., Saraiya, V., Elangovan, S., Allareddy, V., Kinnunen, T., Kornman, K. S., & Duff, G. W. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.110655 · Cited by 161
Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
Yu, J. R., & Leslie, K. S. (2010) · Current Allergy and Asthma Reports · doi:10.1007/s11882-010-0160-9 · Cited by 152
Self-citationRissanen, A., Howard, C. P., Botha, J., Thuren, T., & for the Global Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01637.x · Cited by 140
“In 2009, canakinumab was approved by the US Food and Drug Administration and the European Medicines Agency for treating adults and children aged ≥4 years with cryopyrin-associated periodic syndromes (CAPS), producing durable remissions of these rare inherited inflammatory disorders [20].”
BackgroundNlrp3: An immune sensor of cellular stress and infection
Lamkanfi, M., & Kanneganti, T.-D. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.008 · Cited by 140
Romano, M., Arıcı, Z. S., Piskin, D., Alehashemi, S., Aletaha, D., Barron, K. S., Benseler, S. M., Berard, R. A., Broderick, L., Dedeoğlu, F., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221801 · Cited by 155
Self-citationTolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Rossi-Semerano, L., Fautrel, B., Wendling, D., Hachulla, E., Galeotti, C., Semerano, L., Touitou, I., Koné-Paut, I., & the MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation) (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0228-7 · Cited by 133
“These results are in agreement with those reported in other series [9-13].”
ResultSelf-citationInflammasome biology, molecular pathology and therapeutic implications
Awad, F., Assrawi, E., Louvrier, C., Jumeau, C., Georgin-Lavialle, S., Grateau, G., Amselem, S., Giurgea, I., & Karabina, S.-A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.011 · Cited by 134
Arnold, D. D., Yalamanoglu, A., & Boyman, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888392 · Cited by 155
“Both studies stemmed from the same RCT treating 31 patients with CAPS, 94% of whom suffered from MWS, with either canakinumab or placebo (31, 32).”
BackgroundInfluentialSchlesinger, N., Meulemeester, M. D., Pikhlak, A., Yücel, E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & So, A. K.-L. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3297 · Cited by 139
“Blood samples were assessed for anti-canakinumab antibodies at baseline and at eight weeks post-dose using a validated Biacore® binding assay (Biacore International AB, Uppsala, Sweden) [25].”
MethodKoné‐Paut, I., Lachmann, H. J., Kuemmerle-Deschner, J. B., HACHULLA, E., Leslie, K. S., Mouy, R., Ferreira, A., Lheritier, K., Patel, N. P., Preiss, R., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3535 · Cited by 141
“As reported previously [6], the results of this study indicate that canakinumab is generally well tolerated and is not associated with an increased risk of any particular AE, other than a slightly increased risk of infections.”
BackgroundMethodResultSelf-citationBangert, C., Brunner, P. M., & Stingl, G. (2011) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2011.01.006 · Cited by 170
Innate Immunity and Rheumatoid Arthritis
Gierut, A. K., Perlman, H., & Pope, R. M. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.03.004 · Cited by 154
“Additionally, mutations in NALP3 are responsible for cryopyrin-associated periodic syndromes (88), and NALP3-containing inflammasomes are activated by monosodium urate (MSU) and calcium pyrophosphate dihydrate (CPPD) crystals in gout and pseudogout, respectively (89).”
BackgroundKrause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F., Zuberbier, T., & Maurer, M. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02843.x · Cited by 142
Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome
Mitroulis, I., Skendros, P., & Ritis, K. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.005 · Cited by 149
“Treatment with canakinumab resulted in immediate and lasting disease remission, with a median time until disease flare of 100 days, in all 15 patients [39].”
BackgroundCurrent Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA
Goldbach‐Mansky, R. T. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0165-y · Cited by 139
“Subcutaneous injections of canakinumab every 8 weeks were given to 35 patients in a randomized withdrawal study [ 44 ].”
Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
Boudoulas, K. D., Triposkiadis, F. K., Geleris, P., & Boudoulas, H. K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.003 · Cited by 152
Intracellular sensing of microbes and danger signals by the inflammasomes
Horvath, G. L., Schrum, J. E., De Nardo, C. M., & Latz, E. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01050.x · Cited by 125
“Recently, two anti-IL-1b therapies have been evaluated [rilonacept (63) and canakinumab (64)], and their efficiency and better pharmacology holds great promise for future therapies in CAPS patients.”
BackgroundAn Expanding Role for Interleukin-1 Blockade from Gout to Cancer
Dinarello, C. A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00232 · Cited by 120
Nakagawa, K., González‐Roca, E., Souto, A., Kawai, T., Umebayashi, H., Campistol, J. M., Cañellas, J., Takei, S., Kobayashi, N., Callejas-Rubio, J. L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204361 · Cited by 126
Physical Urticarias and Cholinergic Urticaria
Abajian, M., Schoepke, N., Altrichter, S., Zuberbier, T., & Maurer, M. (2013) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2013.09.010 · Cited by 125
Adult-onset Still's disease: Advances in the treatment
Castañeda, S., Blanco, R., & González-Gay, M. Á. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.08.003 · Cited by 124
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
Fürst, D. E., Keystone, E. C., Braun, J. M., Fc, B., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201036 · Cited by 131
Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3266 · Cited by 121
“The data reported here indicate that canakinumab is well tolerated in children and adolescents, as well as in adults, as reported previously [15] and elsewhere for this study [13].”
BackgroundResultInfluentialSelf-citationInternational multi-centre study of pregnancy outcomes with interleukin-1 inhibitors
Youngstein, T., Hoffmann, P. M., Gül, A., Lane, T., Williams, R., Rowczenio, D. M., Özdoğan, H., Uğurlu, S., Ryan, J., Harty, L., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex305 · Cited by 121
“Maternal diagnoses were CAPS (12), adult onset Still’s Disease (AOSD) (4), FMF (3), TRAPS (2), pericarditis (1), and Cogan syndrome (1).”
BackgroundMethodInfluentialSelf-citationLachmann, H. J. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.12.001 · Cited by 134
Self-citationTargeting NLRP3 Inflammasome Activation in Severe Asthma
Theofani, E., Semitekolou, M., Morianos, I., Samitas, Κ., & Xanthou, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101615 · Cited by 127
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
Fürst, D. E., Keystone, E. C., So, A. K.-L., Braun, J., Breedveld, F. C., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203348 · Cited by 126
Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma
Dunn, J. H., Ellis, L. Z., & Fujita, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.001 · Cited by 124
“including anti-IL-1b monoclonal antibody [124], IL-1Ra [159], IL-1 Trap [160], oral caspase-1 inhibitor [161] and”
BackgroundCanakinumab in adults with steroid‐refractory pyoderma gangrenosum
Kolios, A. G. A., Maul, J., Meier-Schiesser, B., Kerl, K., Traidl‐Hoffmann, C., Hertl, M., Zillikens, D., Röcken, M., Ring, J., Facchiano, A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14037 · Cited by 116
“36 Recently, clinical reports have suggested a therapeutic effect of drugs targeting IL-1 signalling in patients with complex auto-inflammatory syndromes involving PG as a clinical element, namely in PAPA and PASH syndrome (pyoderma, acne and suppurative hidradenitis).”
Precision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Lepore, L., Paloni, G., Caorsi, R., Alessio, M., Rigante, D., Ruperto, N., Cattalini, M., Tommasini, A., Zulian, F., Ventura, A., et al. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.02.040 · Cited by 120
Rowczenio, D. M., Pathak, S., Aróstegui, J. I., Mensa‐Vilaró, A., Omoyinmi, E., Brogan, P. A., Lipsker, D. M., Scambler, T., Owen, R. G., Trojer, H., et al. (2017) · Blood · doi:10.1182/blood-2017-10-810366 · Cited by 116
Self-citationde Koning, H. D., Schalkwijk, J., van der Ven‐Jongekrijg, J., Stoffels, M., van der Meer, J. W. M., & Simon, A. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202192 · Cited by 111
Danger signals activating innate immunity in graft-versus-host disease
Zeiser, R., Penack, O., Holler, E., & Idzko, M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0767-x · Cited by 122
“of IL-1 [117] and autoinflammatory diseases caused by mutations of the interleukin-1-receptor antagonist were”
BackgroundStressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation
Yabal, M., Calleja, D. J., Simpson, D. S., & Lawlor, K. E. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-124r · Cited by 109
Welzel, T., & Kuemmerle-Deschner, J. B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010128 · Cited by 116
Self-citationHensen, J., Howard, C. P., Walter, V., & Thuren, T. Y. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.07.003 · Cited by 115
Gattorno, M., Obici, L. P., Cattalini, M., Tormey, V. J., Abrams, K. B., Davis, N., Speziale, A., Bhansali, S. G., Martini, A., & Lachmann, H. J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209031 · Cited by 108
“Neither of these tools has been validated for use in TRAPS.”
MethodSelf-citationNakamura, Y., Franchi, L., Kambe, N., Meng, G., Strober, W., & Núñez, G. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.013 · Cited by 102
“In the last decade, biological inhibitors of IL-1 signaling or IL-1b antibodies have become the most effective treatments for CAPS patients (Goldbach-Mansky et al., 2006; Hoffman et al., 2008; Lachmann et al., 2009).”
Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M., Church, M. K., & Maurer, M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.041 · Cited by 106
Lopalco, G., Cantarini, L., Vitale, A., Iannone, F., Anelli, M. G., Andreozzi, L., Lapadula, G., Galeazzi, M., & Rigante, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/194864 · Cited by 110
Fury, W., Tremoulet, A. H., Watson, V. E., Best, B. M., Shimizu, C., Hamilton, J. D., Kanegaye, J. T., Wei, Y., Kao, C., Mellis, S. J., et al. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.06.008 · Cited by 107
“A variety of biologic agents target the IL-1 pathway and include anakinra, an IL-1 receptor antagonist, the fusion protein rilonacept (Arcalyst®), and the monoclonal antibody canakinumab (Ilaris®) [28,35,36].”
Gül, A., Özdoğan, H., Erer, B., Uğurlu, S., Kasapçopur, Ö., Davis, N., & Sevgi, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0765-4 · Cited by 102
“There is no study comparing the dynamics of IL-1 beta secretion in patients with crFMF with those in patients with cryopyrinassociated periodic fever syndrome (CAPS) [8, 9].”
MethodThe emerging roles of inflammasome‐dependent cytokines in cancer development
Gorp, H. V., & Lamkanfi, M. (2019) · EMBO Reports · doi:10.15252/embr.201847575 · Cited by 103
“With a molecular weight of about 145 kDa, the mean terminal half-life of Canaki-numab was demonstrated to be 26 days, thus necessitating fewer injections (once a month or fewer) compared to Anakinra [124].”
Regulation of inflammasome activity
Guarda, G., & So, A. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03283.x · Cited by 95
Vats, R., Brzóska, T., Bennewitz, M. F., Jimenez, M. A., Pradhan‐Sundd, T., Tütüncüoğlu, E., Jonassaint, J., Gutierrez, E., Watkins, S. C., Shiva, S., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1370oc · Cited by 108
How not to miss autoinflammatory diseases masquerading as urticaria
Krause, K., Grattan, C., Bindslev‐Jensen, C., Gattorno, M., Kallinich, T., de Koning, H. D., Lachmann, H. J., Lipsker, D. M., Navarini, A. A., Simon, A., et al. (2012) · Allergy · doi:10.1111/all.12030 · Cited by 107
Self-citationvan der Hilst, J. C. H., Moutschen, M. P., Messiaen, P., Lauwerys, B. R., & Vanderschueren, S. (2016) · Biologics · doi:10.2147/btt.s102954 · Cited by 97
Goldbach‐Mansky, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05159.x · Cited by 96
Ozkurede, U., & Franchi, L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04535.x · Cited by 105
Systemic Arthritis in Children: A Review of Clinical Presentation and Treatment
Gurion, R., Lehman, T. J. A., & Moorthy, L. N. (2011) · International Journal of Inflammation · doi:10.1155/2012/271569 · Cited by 94
“The selective IL-1β antibody canakinumab treats genetic fever syndromes, thus identifying this agent as a potential therapeutic modality for sJIA [164].”
BackgroundObici, L. P., Meini, A., Cattalini, M., Chicca, S., Galliani, M., Donadei, S., Plebani, A., & Merlini, G. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143438 · Cited by 93
“In our experience, anakinra is safe and effective in TRAPS, reducing disability and improving everyday life. Skin reactions are frequent but manageable. We support anakinra as first-line treatment for patients with TRAPS who require high-dose glucocorticoids, also in light of the variable efficacy of etanercept that i…”
BackgroundTsai, T., Kuehn, S., Tsiampalis, N., Vu, M.-K., Kakkassery, V., Stute, G., Dick, H. B., & Joachim, S. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194603 · Cited by 96
Sensors of the innate immune system: their link to rheumatic diseases
Theofilopoulos, A. N., González‐Quintial, R., Lawson, B. R., Koh, Y. T., Stern, M. E., Kono, D. H., Beutler, B., & Baccalà, R. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.278 · Cited by 104
“Consequently, a recombinant non glycosylated homolog of the IL-1Ra (anakinra), IL-1R fused to IgG1Fc (rilonacept) and a human anti-IL-1β antibody (canakinumab) have shown remarkable effectiveness in treating these syndromes—even in some patients without NLRP3 mutations”
BackgroundTherapy of autoinflammatory syndromes
Hoffman, H. M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.001 · Cited by 92
“In the one NOMID case in which anakinra was reported to be ineffective, dosing was not increased to greater than 1.6 mg/kg/d.101 In addition to improvement in daily symptoms and systemic markers of inflammation, some patients have also experienced resolution or significant improvement in long-term complications, such…”
InfluentialTherapeutic Monoclonal Antibody Concentration Monitoring: Free or Total?
Kuang, B., King, L., & Wang, H. F. (2010) · Bioanalysis · doi:10.4155/bio.10.64 · Cited by 93
Piram, M., Frenkel, J., Gattorno, M., Özen, S., Lachmann, H. J., Goldbach‐Mansky, R. T., Hentgen, V., Neven, B., Stankovic, K., Simon, A., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.132613 · Cited by 101
Self-citationThe inflammasome: in memory of Dr. Jurg Tschopp
Dagenais, M., Skeldon, A. M., & Saleh, M. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.159 · Cited by 105
“etiology of cryopyrin-associated periodic syndromes (CAPS) to mutations in NLRP3, leading to the now successful therapy of CAPS patients in the clinic.(87) His 2006 discovery that MSU”
BackgroundWang, Y., Wang, J., Zheng, W., Zhang, J., Wang, J., Jin, T., Tao, P., Wang, Y., Liu, C., Huang, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.014 · Cited by 94
Is the inflammasome a potential therapeutic target in renal disease?
Turner, C. M., Arulkumaran, N., Singer, M., Unwin, R. J., & Tam, F. W. K. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-21 · Cited by 96
“Canakinumab, a monoclonal antibody against IL-1β, has a longer half-life compared with the other antagonists, and may be useful in patients with RA and CAPS [104,105].”
BackgroundFlorescu, D. N., Boldeanu, M. V., Șerban, R.-E., Florescu, L. M., Şerbănescu, M.-S., Ionescu, M., Streba, L., Constantin, C., & Vere, C. C. (2023) · Life · doi:10.3390/life13122261 · Cited by 99
Bourigault, M.-L., Segueni, N., Rose, S., Court, N., Vacher, R., Vasseur, V., Erard, F., Bert, M. L., Garcia, I., Iwakura, Y., et al. (2013) · Immunity Inflammation and Disease · doi:10.1002/iid3.9 · Cited by 100
Kontzias, A., & Efthimiou, P. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.03.004 · Cited by 90
The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier
Macleod, T., Berekméri, A., Bridgewood, C., Stacey, M. A., McGonagle, D., & Wittmann, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808012 · Cited by 97
Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases
Murakami, T., Nakaminami, Y., Takahata, Y., Hata, K., & Nishimura, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105365 · Cited by 94
“For example, anakinra is a recombinant IL-1Ra that has been approved for RA treatment [180], and canakinumab is a human anti-IL-1β monoclonal antibody used for CAPS treatment [181].”
MethodInflammasome: structure, biological functions, and therapeutic targets
Dai, Y., Zhou, J., & Shi, C. (2023) · MedComm · doi:10.1002/mco2.391 · Cited by 98
Geusau, A., Mothes‐Luksch, N., Nahavandi, H., Pickl, W. F., Wise, C. A., Pourpak, Z., Ponweiser, E., Eckhart, L., & Sunder‐Plaßmann, R. (2013) · JAMA Dermatology · doi:10.1001/2013.jamadermatol.717 · Cited by 89
The emerging role of interleukin‐1β in autoinflammatory diseases
Lachmann, H. J., Quartier, P., So, A. K.-L., & Hawkins, P. N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30105 · Cited by 97
Self-citationMicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies
Tezcan, G., Martynova, E. V., Gilazieva, Z. E., McIntyre, A., Rizvanov, A. A., & Khaiboullina, S. F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00451 · Cited by 85
Pharmacotherapy for uveitis: current management and emerging therapy
Denniston, A. K., Barry, R. J., Nguyen, Q. D., Lee, R., & Murray, P. I. (2014) · Clinical ophthalmology · doi:10.2147/opth.s47778 · Cited by 96
“It is usually administered by subcutaneous injection every 4–8 weeks, but can also be given intravenously.(245) It has been used to successfully treat uveitis associated with BD(246) and Blau syndrome,(247) but data is currently limited to case reports only.”
Arranz, L., Arriero, M. D. M., & Villatoro, A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.05.001 · Cited by 95
“This is a substantial advantage over anakinra and rilonacept, given that canakinumab is administered bimonthly, as opposed to the weekly or daily injections with rilonacept or anakinra, respectively [173].”
BackgroundKuemmerle-Deschner, J. B., Verma, D., Endres, T., Broderick, L., de Jesus, A. A., Hofer, F., Blank, N., Krause, K., Rietschel, C., Horneff, G., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40208 · Cited by 86
“Treatment responses were defined as follows (8); a complete response was defined as no or minimal disease activity, as demonstrated by a DAS for MWS of ≤5, no rash and normal CRP (<0.”
MethodSelf-citationBilginer, Y., Akpolat, T., & Özen, S. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-1797-x · Cited by 91
Inflammasome and cytokine blocking strategies in autoinflammatory disorders
Moll, M., & Kuemmerle-Deschner, J. B. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.008 · Cited by 90
Self-citationHave we overestimated the benefit of human(ized) antibodies?
Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M. L., & Miller, S. D. (2010) · mAbs · doi:10.4161/mabs.2.6.13601 · Cited by 98
Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk
Ait‐Oufella, H., Libby, P., & Tedgui, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311998 · Cited by 88
The role of interleukin-1 in allergy-related disorders
Krause, K., Metz, M., Makris, M. P., Zuberbier, T., & Maurer, M. (2012) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283574d0c · Cited by 94
“Within the autoinflammatory disorders, CAPS and SchS are regularly associated with urticarial rash.”
BackgroundInfluentialCell death–mediated cytokine release and its therapeutic implications
Place, D. E., & Kanneganti, T.-D. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181892 · Cited by 84
“IL-18 is also thought to contribute to the pathogenesis of a number of skin diseases, including psoriasis, atopic dermatitis, and lupus, but more definitive studies are needed to determine whether inhibition with IL-18 binding protein (IL-18BP) will be beneficial (Lee et al., 2015).”
BackgroundMonogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues
Caso, F., Rigante, D., Vitale, A., Lucherini, O. M., Costa, L., Atteno, M., Compagnone, A., Caso, P., Frediani, B., Galeazzi, M., et al. (2013) · International Journal of Rheumatology · doi:10.1155/2013/513782 · Cited by 93
“The safety and tolerability of rilonacept have been demonstrated in a group of pediatric and adult CAPS patients, while canakinumab has been shown to be safe and effective both in controlling clinical/laboratory indicators of disease activity and in controlling amyloidosisrelated complications [14, 99–101].”
BackgroundSoriano, A., Soriano, M., Espinosa, G., Manna, R., Emmi, G., Cantarini, L., & Hernández‐Rodríguez, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00865 · Cited by 91
Effect of interleukin 1β inhibition in cardiovascular disease
Qamar, A., & Rader, D. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328359b0a6 · Cited by 80
“Significant reduction in C-reactive protein and serum amyloid A levels were observed after treatment with canakinumab in patients with CAPS, gout, and type 2 diabetes [13,46,47].”
BackgroundNeurologic manifestations of the cryopyrin-associated periodic syndrome
Kitley, J., Lachmann, H. J., Pinto, A. A., & Ginsberg, L. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d9ed69 · Cited by 83
Self-citationMimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases
Davis, M. D. P., & van der Hilst, J. C. H. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.05.006 · Cited by 83
Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes
Lei, Y., Devarapu, S. K., Motrapu, M., Cohen, C. D., Lindenmeyer, M. T., Moll, S., Kumar, S. V. R., & Anders, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01223 · Cited by 82
Inflammasome inhibitors: promising therapeutic approaches against cancer
Xu, S., Li, X., Liu, Y., Xia, Y., Chang, R., & Zhang, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0755-0 · Cited by 86
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome
Krause, K., Feist, E., Fiene, M., Kallinich, T., & Maurer, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.031 · Cited by 82
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases
Aksentijevich, I. A., & Schnappauf, O. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00614-1 · Cited by 85
Dubois, E. A., Rißmann, R., & Cohen, A. F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03958.x · Cited by 79
Canakinumab for the treatment of chronic obstructive pulmonary disease
Rogliani, P., Calzetta, L., Ora, J., & Matera, M. G. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.01.005 · Cited by 80
Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders
Vitale, A., Rigante, D., Lucherini, O. M., Caso, F., Muscari, I., Magnotti, F., Brizi, M. G., Guerrini, S., Patti, M. L., Punzi, L., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/939847 · Cited by 82
“The first double-blind, randomized trial was completed in 2008 and established that treatment with canakinumab 150mg (or 2mg/kg for children) every eight weeks was associated with a rapid remission of symptoms in the great majority of patients with CAPS [103].”
BackgroundLiang, J., Alfano, D. N., Squires, J. E., Riley, M. M., Parks, W. T., Kofler, J., El‐Gharbawy, A., Madan‐Khetarpal, S., Acquaro, R., & Picarsic, J. L. (2017) · Pediatric and Developmental Pathology · doi:10.1177/1093526616686890 · Cited by 78
Autoinflammatory diseases: State of the art
Georgin‐Lavialle, S., Fayand, A., Rodrigues, F., Bachmeyer, C., Savey, L., & Grateau, G. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2018.12.003 · Cited by 80
Neonatal autoimmune diseases: A critical review
Chang, C. C.-C. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.11.018 · Cited by 83
Choon, S. E., Lebwohl, M., Marrakchi, S., Burden, A. D., Tsai, T., Morita, A., Navarini, A. A., Zheng, M., Xu, J., Turki, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043666 · Cited by 77
Bettiol, A., Lopalco, G., Emmi, G., Cantarini, L., Urban, M. L., Vitale, A., Denora, N., Lopalco, A., Cutrignelli, A., Lopedota, A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081898 · Cited by 77
“However, a slightly increased rate of non-serious infections related to the upper respiratory tract has been observed [26].”
BackgroundMethodInfluentialBou-Dargham, M. J., Khamis, Z. I., Cognetta, A. B., & Sang, Q. A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21406 · Cited by 79
Burns, J. C., Koné‐Paut, I., Kuijpers, T. W., Shimizu, C., Tremoulet, A. H., & Arditi, M. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39975 · Cited by 76
A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges
Hossen, M. S., Barek, M. A., Jahan, N., & Islam, M. S. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00485-9 · Cited by 77
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.